

Oregon Prescription Drug Monitoring Program Advisory Commission

January 16, 2015 Meeting Minutes

1:00 PM to 4:00 PM

Portland State Office Building

800 NE Oregon Street, Room 368

Portland, OR 97232

ATTENDEES:

Advisory Commission Present: Mike Millard, Chris Apgar, Katrine Benggaard, Lindsay Jenkins, Bill Jordan, Sara Love, John Mcilveen, Mark Williams

Advisory Commission Absent: Larisa Jeffries, Tracy Muday, Laura Scobie

OHA Staff: Todd Beran, Bruce Gutelius, Lisa Millet, Heidi Murphy, Stephanie Vesik

Guests: Al Turner

Decisions
1. The meeting minutes from October 2014 were approved as written.
2. The draft 2014 Annual Report to the PDMP Advisory Commission was approved with minor edits.

Action Items	Assigned	Status
1. Incorporate draft edits to final copy of 2014 Annual Report to the PDMP Advisory Commission.	Beran	
2. Revise practice specialty list and distribute to members for review.	Beran	

INTRODUCTIONS

Millard called the meeting to order at 1:10 p.m. Attendees introduced themselves.

OLD BUSINESS

The meeting minutes were reviewed and approved as written – see Decision 1.

STANDING AGENDA ITEMS

a. Review quarterly metrics

Beran presented highlights of the 2014 fourth quarter report. He stated that healthcare providers, pharmacists, and delegates conducted greater than 210,000 patient queries,

the highest quarterly amount to date. He also stated that in 2014, PDMP staff authenticated and activated more than 3,000 new accounts.

b. BJA Grant Update

Beran noted that major grant activities are referenced in the 2014 Annual Report to the PDMP Advisory Commission.

NEW BUSINESS

a. Review 2014 PDMP Advisory Commission Annual Report

Beran reviewed a draft copy of the 2014 Annual Report to the PDMP Advisory Commission. Highlights included significant increases in the number of system users and the number of patient reports queried. Beran noted that these increases were largely driven by the legislative change allowing office staff delegated access to PDMP information on behalf of healthcare providers and pharmacists. Millard stated that the notary process to apply for an account remains a significant barrier to sign up. Apgar noted that the notarization process is currently the best method to ensure that the individuals applying for accounts are who they say they are. See Decision 2 and Action Item 1.

b. Discuss PDMP-AC recommendations

Millet reviewed the recommendations listed in the 2014 Annual Report to the PDMP Advisory Commission. She noted the significant development of the PDMP over the first three years of operation. As the program has grown, some key issues related to program evaluation have been identified. Partnering with researchers to evaluate the PDMP is an essential part of the process, but staff resources are needed to work with researchers to link and de-identify PDMP data. Millet noted the preliminary 2014 death data indicate a continued decrease in prescription drug and heroin overdose deaths. She also discussed collecting unintentional overdose data in the Oregon National Violent Death Reporting System (OrNVDRS) to improve overdose surveillance.

c. Discuss research study vetting, data use agreements, IRB processes, and oversight roles

Millet discussed the new research study vetting process developed by the program to align with the Public Health Division's processes. Projects are reviewed for scientific merit to ensure they align with programmatic goals. She proposed that the Advisory Commission or a subcommittee of members conduct a cursory review of new studies following final review by the program and prior to OHA IRB submission. The purpose of this review is to make members aware of proposed projects and gather

additional perspectives related to the merits and implications of the research. Members agreed that this would be a good role for the Advisory Commission. Millard proposed that research studies be presented after Advisory Commission meetings have concluded to make the review optional and convenient for members.

OPEN ISSUES

Millard stated that there is a bill being proposed during the 2015 legislative session that could affect the timeframe within which pharmacies are required to report. Increasing frequency is not supported by pharmacies as it creates a hardship.

Beran stated that Tracy Muday has resigned from the Advisory Commission. He is working with the Oregon Medical Association to identify her replacement.

Members thanked Al Turner for his years of service on the Advisory Commission.

Beran noted that terms for the following Advisory Commission members will end in July 2015: Bengaard, Jeffreys, and Mcilveen. Staff will contact these members before the next Advisory Commission meeting to determine who would like to be reappointed.

Members reviewed the provider specialty list discussed at the July 2014 meeting. Turner and Bengaard requested that “Osteopathic Manipulative Medicine” be added. Members also agreed that that “Family Medicine w/urgent care” was unnecessary. See Action Item 2.

PUBLIC COMMENT

No public comments were made.

NEXT MEETING DATE

The next PDMP Advisory Commission meeting will be on Friday, April 17th, 2015 in room 918 at the Portland State Office Building.

ADJOURNMENT

The meeting was adjourned at 3:05 PM.